ReviewDrugs2021
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 415 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
415 citing papers in PubMed, 3 syntheses or guidelines pooled it, 630 citations in OpenAlex.
- Worldwide threatening prevalence of carbapenem-resistantEpidemiology and infection · 2025Pooled it
- Antibiotic resistance in hospital wastewater in West Africa: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Dominance of antimicrobial resistance bacteria and risk factors of bacteriuria infection among pregnant women in East Africa: implications for public health.Journal of health, population, and nutrition · 2025Pooled it
- Redox protection by bacterial glutathione peroxidase drives virulence inRedox report : communications in free radical research · 2026Article
- α-Mangostin attenuatesVirulence · 2026Article
- Furin inhibition protects against acute lung injury in a mouse model of Pseudomonas aeruginosa infection.American journal of respiratory cell and molecular biology · 2026Article
- Molecular Insight into the Inhibition ofACS omega · 2026Article
- Invasive Pulmonary Aspergillosis-MimickingJournal of Korean medical science · 2026Article
- Isolation and genomic characterization of bacteriophage Vanta, a lyticMicrobiology resource announcements · 2026Article
- Isolation and genomic characterization of bacteriophage Luminis, a lyticMicrobiology resource announcements · 2026Article
- Comparison ofInfection and immunity · 2026Article
- A multivalent subunit vaccine augments pre-existing immunity to protect against T3SS-positiveInfection and immunity · 2026Article
- Enumeration Method forMicroorganisms · 2026Article
- Effects of Magnesium and Calcium Cations on Antibiotic Susceptibility ofAntibiotics (Basel, Switzerland) · 2026Article
- Antibacterial and antibiofilm properties of 1,3,4-oxadiazoles against multidrug-resistant Pseudomonas aeruginosa isolated from burn infections - an in vitro study.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- TypA Interacts with ExsA to Suppress Type III Secretion System inMicroorganisms · 2026Article
- Structural and functional insights into Pseudomonas aeruginosa ApaH, a diadenosine tetraphosphatase crucial for bacterial virulence.Protein science : a publication of the Protein Society · 2026Article
- Prevalence and Antimicrobial Resistance ofInfectious disease reports · 2026Article
- Inhaled sphingosine reduces bronchial Pseudomonas aeruginosa burden during porcine ex vivo lung perfusion and shows tissue delivery in explanted human lungs.Scientific reports · 2026Article
- Transient sub-MIC ciprofloxacin exposure produces a stress-conditioned Pseudomonas aeruginosa phenotype that enhances NF-κB activation and inflammatory injury in lung epithelial cells.Archives of microbiology · 2026Article
355 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is a Gram-negative bacterial pathogen that is a common cause of nosocomial infections, particularly pneumonia, infection in immunocompromised hosts, and in those with structural lung disease such as cystic fibrosis. Epidemiological studies have identified increasing trends of antimicrobial resistance, including multi-drug resistant (MDR) isolates in recent years. P. aeruginosa has several virulence mechanisms that increase its ability to cause severe infections, such as secreted toxins, quorum sensing and biofilm formation. Management of P. aeruginosa infections focuses on prevention when possible, obtaining cultures, and prompt initiation of antimicrobial therapy, occasionally with combination therapy depending on the clinical scenario to ensure activity against P. aeruginosa. Newer anti-pseudomonal antibiotics are available and are increasingly being used in the management of MDR P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.